11 Capital Partners LP Trims Stock Holdings in Danaher Co. (NYSE:DHR)

11 Capital Partners LP lowered its holdings in Danaher Co. (NYSE:DHR) by 57.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,039 shares of the conglomerate’s stock after selling 27,300 shares during the period. Danaher comprises 1.9% of 11 Capital Partners LP’s portfolio, making the stock its 12th largest position. 11 Capital Partners LP’s holdings in Danaher were worth $5,007,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Benjamin Edwards Inc. boosted its position in Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after purchasing an additional 38 shares during the last quarter. Patrick M Sweeney & Associates Inc. boosted its position in Danaher by 3.4% during the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after purchasing an additional 40 shares during the last quarter. Trust Co of Kansas boosted its position in Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares during the last quarter. Abacus Planning Group Inc. boosted its position in Danaher by 0.7% during the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares during the last quarter. Finally, ST Germain D J Co. Inc. boosted its position in Danaher by 1.4% during the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is currently owned by corporate insiders.

Danaher Stock Down 1.4 %

Shares of DHR opened at $272.63 on Friday. The company has a market capitalization of $201.93 billion, a P/E ratio of 46.21, a PEG ratio of 4.48 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The business’s 50 day simple moving average is $267.62 and its 200-day simple moving average is $257.14.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue was down 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.05 EPS. As a group, sell-side analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is 18.31%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Royal Bank of Canada restated an “outperform” rating and set a $300.00 target price on shares of Danaher in a report on Friday, September 6th. TD Cowen raised their target price on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Evercore ISI cut their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price on the stock. Finally, Leerink Partners raised their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.